Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Retail giant Walmart has teamed up with Transcarent, a health and care platform, to provide a go-to-market solution for self-insured employers and their families.
Walgreens Boots Alliance has launched a new business arm, Walgreens Health, enabled by investments in VillageMD, a primary care provider, and CareCentrix, a post-acute care company.
A convolutional neural network has proven adept at predicting the spread of colorectal cancer to the lymph nodes using automated analysis of histology slides.
Harvard researchers have demonstrated a web-based program that allows cognitively normal individuals to screen themselves, unsupervised, for the type of memory decline that may signal encroaching Alzheimer’s disease.
Cambridge University researchers propose using the technique to predict individuals’ health issues over time and intervene early with personalized preventive care.
In cancer research settings, AI has shown strong capabilities for predicting risk, recurrence and survivability over the past 10-plus years. Yet real-world cancer mortality remains largely unchanged to the present day. Why is that?
The American College of Cardiology has sent a letter to HHS Secretary Robert F. Kennedy Jr. that outlines some of the organization’s central priorities and concerns.
If the Trump administration continues taking a laissez-faire stance toward AI—including AI used in healthcare—why not let the states go it alone on regulating the technology?
